Peer Exchange

EP. 1: C. Difficile Risk Factors and Manifestation

EP. 2: Strains of C. Difficile

EP. 3: Managing Community-Onset C. Difficile

EP. 4: Recurrent C. Difficile

EP. 5: C. Difficile: A Differential Diagnosis

EP. 6: Testing for C. Difficile Infections

EP. 7: Screening for C. Difficile

EP. 8: C. Difficile: Clinical Practice Guidelines and Treatment Options

EP. 9: C. Difficile: Updates to Clinical Practice Guidelines

EP. 10: Selecting Therapy to Treat C. Difficile

EP. 11: C. Difficile Treatment: Fidaxomicin

EP. 12: Choosing Between Vancomycin and Fidaxomicin for C. Difficile Infections

EP. 13: C. Difficile Treatment: Bezlotoxumab

EP. 14: Preventing/Treating C. Difficile: Unmet Needs

EP. 15: Fecal Microbiota Transplantation for C. Difficile Infections

EP. 16: Emerging Treatment Options for C. Difficile Infections

EP. 17: C. Difficile: Barriers Treating With FMT

EP. 18: Making Strides in the Management of C. Difficile

EP. 1: Burden of HIV in the USA and Associated Symptoms

EP. 2: Screening Recommendations for HIV and Risk Stratification

EP. 3: PrEP Therapy for High-Risk HIV Candidates

EP. 4: Safety Profiles of FDA-Approved PrEP Agents

EP. 5: State Medicaid Reimbursement for Routine HIV Screening

EP. 6: Rapid Initiation of HIV Treatment With ART

EP. 7: Factors Considered in Choosing Initial HIV Therapeutic Regimen

EP. 8: Safety Profile and Costs of Initial HIV Therapeutic Regimen

EP. 9: Switching Therapies in Patients Who Are Successfully Treated

EP. 10: Virological Failure or Rebound to HIV Therapies

EP. 11: Emerging Treatment Options for HIV

EP. 12: Drug Resistance or Intolerance to HIV Therapy

EP. 13: Long-Acting Injectables to Treat HIV

EP. 14: Long-Acting Injectables as PrEP Therapy

EP. 1: The HIV Treatment Landscape

EP. 2: HIV Screening and Diagnosis

EP. 3: HIV Pre-Exposure Prophylaxis Therapy

EP. 4: HIV Treatment: Initiation, Adherence, and Accessibility

EP. 5: HIV US Preventive Task Force Screening Recommendations

EP. 6: HIV: Undetectable Equals Untransmittable

EP. 7: HIV Therapy Selection for the General Population

EP. 8: HHS vs IAS-USA Guidelines for HIV

EP. 9: HIV Treatment Options for Pregnant Women

EP. 10: Dolutegravir + Rilpivirine Combination Therapy for HIV

EP. 11: The Difficulty of Switching ART Regimens in HIV

EP. 12: Recommended HIV-Monitoring Approach for Stable Patients

EP. 13: Virological Failure and Incomplete Response in HIV

EP. 14: Significance of Low-Level Viremia Indication in HIV

EP. 15: HIV Long-Acting Injectable Therapies in Development

EP. 16: HIV Noninjectable Long-Acting Therapies in Development

EP. 1: An Overview of ABSSSI

EP. 2: Understanding the Prevalence of ABSSSI in the Community

EP. 3: ABSSSI: Standard Protocol of Admission and Treatment

EP. 4: Cost Considerations of IV Antibiotics for ABSSSI

EP. 5: Oral Antibiotic Compliance for ABSSSI

EP. 6: Treatment of ABSSSI: Inpatient Versus Outpatient

EP. 7: ABSSSI: Outpatient Parenteral Antibiotic Therapy

EP. 8: Determining the Severity of ABSSSI

EP. 9: Lipoglycopeptide Therapies for Gram-Positive Infections

EP. 10: Gram-Positive ABSSSI: Early Identification and Follow-Up

EP. 11: ABSSSI Case Scenarios for OPAT

EP. 12: Trends of ABSSSI Incidence in the Community

EP. 13: Establishing Real-World Protocols for OPAT

EP. 14: OPAT Protocols: Navigating Challenges

EP. 15: Lipoglycopeptide Antibiotics for ABSSSI: Education

EP. 16: Standard Protocol for the Treatment of ABSSSI

EP. 17: Cost Considerations for the Treatment of ABSSSI

EP. 18: Risk Stratification for ABSSSI

EP. 19: Long-Acting Lipoglycopeptide Antibiotics for ABSSSI

EP. 20: Establishing a Protocol for OPAT

EP. 21: Future of OPAT for ABSSSI

EP. 1: Pseudomonas Infections in the ICU: Who's Susceptible?

EP. 2: Pseudomonas Infections: Matching Causes and Prevention

EP. 3: Pseudomonas Infections in the ICU Versus on the Floor

EP. 4: Pseudomonas Infections: Nuancing the Use of Antibiotics

EP. 5: Fighting Pseudomonas: Impact On Patient Prognosis & Approaches to Combat Infection

EP. 6: Classes and Agents Available to Treat Pseudomonas Infections

EP. 7: Pseudomonas Infections Continue to Acquire Resistance, Complicating Treatment

EP. 8: Exploring Cephalosporin/β-Lactamase Inhibitor Combinations for Treatment of Pseudomonas

EP. 9: Exploring Appropriate Treatment Protocols for Pseudomonas Infections

EP. 10: Core Challenges in Pseudomonas Treatment Protocol

EP. 11: Pseudomonas Infections: Optimizing Diagnostic Strategies

EP. 12: Pseudomonas Infections: Selecting Upfront Antibiotics

EP. 13: Pseudomonas Infections: Secondary Approach to Treatment

EP. 14: Treating Pseudomonas Infections With Zerbaxa or Avycaz

EP. 15: Zerbaxa and Avycaz: Considerations for Treatment

EP. 16: The Future Treatment of Pseudomonas Infections

EP. 1: An Overview of Multidrug-Resistant Bacterial Infections

EP. 2: Understanding the Causes and Impact of MDR Infections

EP. 3: MDR Infections: Current Pathogen and Treatment Paradigm

EP. 4: Gram-Negative Nosocomial Infections: Systemic Risk

EP. 5: Factors in Choosing Therapy for Gram-Negative NIs

EP. 6: Diagnostic Tests for Gram-Negative Nosocomial Infections

EP. 7: Gram-Negative NIs: Vabomere and the TANGO II Study

EP. 8: Gram-Negative NIs: Cephalosporin/β-Lactamase Inhibitors

EP. 9: Understanding Gram-Positive Nosocomial Infections

EP. 10: Selecting Lipoglycopeptide Therapy for Gram-Positive NIs

EP. 11: Gram-Positive NIs: Nuancing Lipoglycopeptide Therapy

EP. 12: Gram-Positive NIs: Costs of Lipoglycopeptide Therapy

EP. 13: MDR Infections: Overview of Antimicrobial Stewardships

EP. 14: Importance of Technology & Data Within Antibiotic Stewardship Programs

EP. 15: Antimicrobial Stewardship Programs: Goals and Challenges

EP. 16: Multidrug-Resistant Bacterial Infections: Key Messages

Peer Exchange

Expert Perspectives on Advances in the Management of C. difficile

Advances in the Treatment Landscape for HIV

HIV Screening, Prevention, and Treatment Advances

Outpatient Management of Acute Bacterial Skin and Skin Structure Infections

Battling Against Resistant Pseudomonas Infections in the ICU

Outsmarting Resistant Infections